caution larry

Hi, I’m Kim! This site provides a little insight to my journey of being diagnosised with Remitting Relapsing Multiple Sclerosis on October 26th 2004. I review books and documentaries, post MS-related news, and share my photos.

Subscribe (RSS)

no larry

My bloglines



November 2004
December 2004
January 2005
February 2005
March 2005
April 2005
May 2005
June 2005
July 2005
August 2005
September 2005
October 2005
November 2005
December 2005
January 2006
February 2006
March 2006
April 2006
May 2006
June 2006
July 2006
August 2006
September 2006
October 2006
November 2006
December 2006
January 2007
February 2007
March 2007
April 2007
May 2007
June 2007
July 2007
August 2007
September 2007
October 2007
November 2007
December 2007
January 2008
February 2008
March 2008
April 2008
May 2008
June 2008
July 2008
August 2008
September 2008
October 2008
November 2008
December 2008
January 2009
February 2009
March 2009
April 2009
May 2009
June 2009
July 2009
August 2009
September 2009
October 2009
November 2009
December 2009
January 2010
February 2010
March 2010
May 2010
June 2010
July 2010
September 2010
November 2011


Monday, March 17, 2008
No more Rebif site reactions?
Nicely done Merck Serono. They've created a new formulation of Rebif that is producing less site reactions. The report sites that people will stop treatment from site reactions. Have you done this?

"In a recent two-year (96 week) Phase IIIb study, 260 patients with relapsing remitting multiple sclerosis treated with the new formulation experienced a near three-fold reduction in injection-site reactions. These results are compared with historical data for the previous formulation of Rebif (30.8% versus 85.8%)1.

"Rebif is an established first line disease modifying treatment for relapsing types of MS" said Professor Gavin Giovannoni from The Royal London Hospital. "Injection site reactions can lead to discontinuation of therapy in some patients2, the notable reduction in these reactions with Rebif New Formulation has positive implications for treatment tolerability and adherence."

Rebif has a favorable benefit-to-risk profile3 and has a proven efficacy and safety profile, which has been demonstrated consistently across numerous phase III clinical trials and clinical practice1,4-6. The new formulation has consistent efficacy compared with previous experience1. At 96 weeks, 53.3% of patients remained relapse-free and overall the expanded disability status scale (EDSS) score remained stable throughout the study1.

The New Formulation of Rebif is the first and only therapy for multiple sclerosis that is serum-free both from animal (foetal bovine serum) and human (human serum albumin) derived components in either the manufacturing process or as excipients.

The new formulation of Rebif® was approved on August 10, 2007, by the European Commission and will be phased in to replace Rebif® original formulation from 1st March 2008.